Does p53 contribute to Cisplatin Induced Renal Oxidative Damage via Regulating P66shc and MnSOD?
Our study identifies activation of p53 signalling as a potential strategy for reducing the nephrotoxicity associated with cisplatin treatments and, as a result, broadens the therapeutic window of this chemotherapeutic agent.
Our findings suggest that the CBM improves the efficiency of these cellulases by enabling digestion within the bulk of the film.